Lipotropin HCL-AOD 9604 is a research peptide studied for fat metabolism. Learn how it works, typical dosing research, side effects, and safety.
Lipotropin HCL-AOD 9604 is a synthetic fragment of human growth hormone (HGH 176-191) sold as a research chemical, not an approved medication. It has been studied for its effects on fat metabolism, but it is not FDA-approved for weight loss or any other human use in the United States.
Suppliers use several names for the same molecule, including lipotropin HCL, AOD 9604, AOD-9604, and HGH fragment 176-191. Those labels point to the same 15-amino-acid peptide.
What Is Lipotropin HCL-AOD 9604?
Researchers designed this fragment to isolate the fat-metabolizing portion of HGH while leaving out the parts linked to growth and blood sugar effects. It corresponds to the C-terminal region of the hormone, known as HGH 176-191.
Laboratory work suggests the fragment does not raise IGF-1 the way full-length HGH does, and it does not appear to act through the growth hormone receptor. Those findings are why it draws interest as a targeted metabolic research compound.
On the gray market, "lipotropin HCL" and "AOD 9604" are often used interchangeably. Label names vary widely and do not guarantee the identity, purity, or sterility of what is inside a vial.
How AOD 9604 Is Studied for Fat Metabolism
AOD 9604 was originally developed as a candidate anti-obesity drug and was tested in human clinical trials during the 1990s and 2000s. Trial results showed only modest effects on body weight, and development for obesity was discontinued.
The proposed mechanism involves stimulating lipolysis, the breakdown of stored triglycerides into free fatty acids, and limiting lipogenesis, the formation of new fat. Some early research also explored effects on cartilage and joint tissue.
AOD 9604 is not a GLP-1 receptor agonist. It works through a different pathway than semaglutide, tirzepatide, or retatrutide, which is one reason it is rarely studied today as a standalone obesity treatment.
AOD 9604 Dosage in Research Settings
There is no FDA-approved human dose of AOD 9604, because the compound is not an approved drug. Published trials and online protocols describe very different numbers, so any figure below is research context rather than medical guidance.
| Setting | Route | Reported amount | Notes |
|---|---|---|---|
| 1990s–2000s human trials | Oral | About 1 mg per day | Development stopped after modest weight-loss results |
| Research-community protocols | Subcutaneous injection | 250–500 mcg per day, sometimes split | No published human dosing data supports this range |
| Stacked self-reported use | Subcutaneous injection | Varies by user | Combined with other peptides or GLP-1 drugs |
Anyone searching for an "aod 9604 dosage" chart will find conflicting advice from vendors and forums. No reliable dose-response data exists for injected AOD 9604, and self-dosing carries unknown risks.
AOD 9604 Reconstitution and Handling
The peptide usually ships as a lyophilized, or freeze-dried, powder that must be dissolved before laboratory use. Standard research practice is to add bacteriostatic water slowly down the inside wall of the vial instead of spraying it directly onto the powder.
- Swab the stopper with an alcohol pad and let it dry before inserting a needle.
- Add the diluent slowly and swirl gently; never shake the vial, because agitation can degrade the peptide.
- Refrigerate the reconstituted vial at 2–8°C (36–46°F) and keep it out of light.
- Write down the mixing date and follow the supplier's stability guidance.
Exact aod 9604 reconstitution steps depend on vial size and diluent volume, and incorrect unit conversion is one of the most frequently reported mistakes. A pharmacist or healthcare professional can double-check the math when a prescription product is involved.
How AOD 9604 Compares to Tesamorelin, MOTS-c, and Retatrutide
| Compound | How it works | Main research or approved use | US regulatory status |
|---|---|---|---|
| Lipotropin HCL-AOD 9604 | HGH fragment 176-191; promotes lipolysis | Fat metabolism research | Not FDA-approved |
| Tesamorelin | GHRH analog; raises endogenous growth hormone | Visceral fat in HIV-associated lipodystrophy | FDA-approved for that indication |
| MOTS-c | Mitochondrial-derived peptide | Insulin sensitivity and metabolic research | Not FDA-approved |
| Retatrutide | Triple GLP-1, GIP, and glucagon agonist | Obesity, still investigational | Not FDA-approved |
| Tirzepatide | Dual GIP and GLP-1 agonist | Type 2 diabetes and chronic weight management | FDA-approved |
The aod 9604 vs tesamorelin question comes down to mechanism. Tesamorelin raises your own growth hormone and has an approved indication with a defined dose, while AOD 9604 is a direct fragment that does not act on the growth hormone receptor.
Comparing aod 9604 vs retatrutide highlights the gap in evidence. Retatrutide has produced substantial weight loss in large randomized trials, whereas AOD 9604 trials showed modest results and were never completed for approval.
Some people also ask about combining AOD 9604 with tirzepatide. No published human data exists on that pairing, and each compound carries its own side effect profile.
AOD 9604 Benefits and Side Effects Reported
Most reported aod 9604 benefits and side effects come from small trials, vendor marketing, and anonymous user posts, so the overall evidence quality is low. Human trials did not show dramatic fat loss, and development stopped after results fell short of commercial targets.
Side effects described in trials and self-reported use include:
- Injection-site redness, swelling, or pain
- Headache
- Mild nausea or digestive upset
- Fatigue
Serious adverse events were not a prominent finding in short trials, but those studies were small and brief. Long-term safety data for AOD 9604 does not exist.
Legal Status and Safety Considerations
AOD 9604 is not FDA-approved for human use in the United States. Products sold as lipotropin HCL are typically labeled "for research use only" and are not evaluated by the FDA for purity, sterility, or potency.
Because these compounds bypass pharmaceutical manufacturing standards, contamination and incorrect labeling are real risks. A third-party certificate of analysis is a minimum check, though such documents can be falsified.
Weight-loss peptides can interact with medications and health conditions. Anyone considering a research peptide should speak with a licensed healthcare professional first, especially when taking diabetes medication or blood thinners, or when there is a history of hormone-sensitive conditions.
Bottom Line
Lipotropin HCL-AOD 9604 is a research peptide derived from HGH 176-191 that has been studied for fat metabolism but never approved for human use. Human trial evidence for meaningful fat loss is modest and incomplete.
Consumers should treat vendor claims as marketing rather than medicine and rely on FDA-approved options discussed with a clinician.
Frequently Asked Questions
Is lipotropin HCL the same as AOD 9604?
In the research-peptide market, both names refer to the synthetic HGH fragment 176-191, so they are generally treated as the same compound. Because these products are unregulated, the label name does not guarantee the actual contents or purity of a vial.
Does AOD 9604 actually work for weight loss?
Human trials conducted in the 1990s and 2000s found only modest effects on body weight, and development for obesity was discontinued. AOD 9604 is not FDA-approved for weight loss, and no strong evidence supports it as a standalone fat-loss drug.
Is AOD 9604 safe for humans?
Short human trials did not report major safety signals, but those studies were small and brief, so long-term safety is unknown. Unregulated products add risks of contamination, mislabeling, and dosing errors, and anyone considering AOD 9604 should consult a healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.